Faculty Profiles - KANDA Mitsuro

Papers - KANDA Mitsuro

Division display 21 - 40 of about 573 ／ All the affair displays >>

術後合併症の予測と対策ドレーンアミラーゼ値を用いた腹腔内感染症の早期予測法 Reviewed

中西香企, 神田光郎, 田中千恵, 杉田静紀, 清水大, 宮田一志, 藤原道隆, 江畑智希, 小寺泰弘

日本胃癌学会総会記事 Vol. 96回 page： 179 - 179 2024.2

血清胃癌診断マーカーとしてのstromal cell-derived factor 4の同定 Reviewed

篠塚高宏, 神田光郎, 中西香企, 清水大, 田中千恵, 梅田晋一, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 中山吾郎, 藤原道隆, 小寺泰弘

日本胃癌学会総会記事 Vol. 96回 page： 307 - 307 2024.2

Development of Unmanned Remote System to Find Radiation Sources Based on 4π Gamma Imaging Reviewed

Mukai, A; Kanda, M; Shimazoe, K; Ishida, F; Takada, E; Tamura, Y; Woo, H; Takahashi, H; Uenomachi, M; Asama, H; Kawarabayashi, J; Tanabe, K; Tsuchiya, K; Kamada, K; Tomita, H

JOURNAL OF ROBOTICS AND MECHATRONICS Vol. 36 ( 1 ) page： 79 - 87 2024.2

早期胃癌に対する低侵襲手術におけるIndocyanine Green蛍光マーキングの有用性 Reviewed

冨永奈沙, 田中千恵, 中西香企, 清水大, 神田光郎, 中山吾郎, 藤原道隆, 小寺泰弘

日本胃癌学会総会記事 Vol. 96回 page： 465 - 465 2024.2

当科における噴門側胃切除術後再建の治療成績 Reviewed

田中千恵, 中西香企, 清水大, 神田光郎, 藤原道隆, 小寺泰弘

日本胃癌学会総会記事 Vol. 96回 page： 265 - 265 2024.2

サルコペニアに対する治療戦略と成績胃癌手術におけるサルコペニアが短期成績とADLに与える影響の検討 Reviewed

杉田静紀, 田中千恵, 中西香企, 神田光郎, 小寺泰弘, 江畑智希

日本胃癌学会総会記事 Vol. 96回 page： 206 - 206 2024.2

Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer. Reviewed

Koki Nakanishi, Chie Tanaka, Mitsuro Kanda, Kazushi Miyata, Nozomu Machida, Mitsuru Sakai, Daisuke Kobayashi, Hitoshi Teramoto, Akiharu Ishiyama, Bin Sato, Takashi Oshima, Masaki Kajikawa, Hidenobu Matsushita, Kiyoshi Ishigure, Katsuya Yamashita, Shinichi Fujitake, Satoshi Sueoka, Takahiro Asada, Dai Shimizu, Shizuki Sugita, Yachiyo Kuwatsuka, Osamu Maeda, Satoshi Furune, Kenta Murotani, Yuichi Ando, Tomoki Ebata, Yasuhiro Kodera

Nagoya journal of medical science Vol. 86 ( 1 ) page： 43 - 51 2024.2

Language：English Publishing type：Research paper (scientific journal)

In Japan, systemic chemotherapy is the standard treatment for unresectable, advanced, or recurrent gastric cancer. However, numerous patients with gastric cancer do not receive late-line treatment because of the rapid progression of gastric cancer. Additionally, late-line treatments, such as nivolumab, trifluridine tipiracil (FTD/TPI), or irinotecan, have limited effects on improving clinical symptoms and delaying the onset of symptoms associated with cancer progression. Recently, a combination of FTD/TPI and ramucirumab was reported to have a high response rate in late-line treatment; however, owing to patient selection bias and a high rate of hematologic toxicity in that previous study, this regimen may not be feasible in real-world clinical applications. Our objective is to conduct a single-arm phase II study to assess the safety and efficacy of FTD/TPI plus ramucirumab combination therapy for gastric cancer after third-line treatment under real-world clinical conditions. This study will recruit 32 patients according to eligibility criteria and administer FTD/TPI (35 mg/m2) and intravenous ramucirumab (8 mg/kg). The primary endpoint will be the time to treatment failure. The secondary endpoints will include the overall survival time, progression-free survival time, overall response rate, disease control rate, relative dose intensity, and incidence of adverse events. The results will add new insights for improving the late-line treatment of advanced gastric cancer.

DOI： 10.18999/nagjms.86.1.43

Web of Science

PubMed

Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer. Reviewed International journal

Yao Liang, Osamu Maeda, Kazushi Miyata, Mitsuro Kanda, Shizuki Sugita, Dai Shimizu, Kazuki Nishida, Yasuhiro Kodera, Yuichi Ando

Cancer chemotherapy and pharmacology Vol. 93 ( 2 ) page： 121 - 127 2024.2

Language：English Publishing type：Research paper (scientific journal)

PURPOSE: This study aimed to explore associations between genetic polymorphisms and adverse effects due to preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for esophageal cancer. METHODS: Preoperative DCF (docetaxel, 70 mg/m2/day, day 1; cisplatin, 70 mg/m2/day, day 1; fluorouracil, 750 mg/m2/day, days 1-5) was repeated every 3 weeks for up to three cycles. Genotyping of nine candidate genetic polymorphisms was conducted using blood samples from the enrolled patients. RESULTS: According to a multivariable analysis evaluating 50 patients, grade 3 or worse neutropenia was more likely to occur in those with the ABCC2-24C/T or T/T genotype (rs717620) (OR, 5.30, P = 0.013). Additionally, patients with the TYMS 3'-UTR 0 bp/0 bp genotype (rs151264360) showed a trend toward grade 3 or worse hyponatremia (OR, 0.16, P = 0.005). Grade 2 or worse thrombocytopenia was more likely to occur in patients with the TNF-α-1031C/T or T/T genotype (rs1799964) (OR, 6.30, P = 0.016) and IL-6-634C/C genotype (rs1800796) (OR, 0.18, P = 0.034), and grade 2 or worse anemia was more likely to occur in patients with the MCP-1-2518G/G genotype (rs1024611) (OR, 0.19, P = 0.027). CONCLUSIONS: ABCC2-24C > T (rs717620), TYMS 3'-UTR 6-bp indel (rs151264360), TNF-α-1031T > C (rs1799964) as well as IL-6-634G > C (rs1800796), and MCP-1-2518A > G (rs1024611) polymorphisms might serve as independent and predictive biomarkers for neutropenia, hyponatremia, thrombocytopenia, and anemia, respectively, during preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for patients with esophageal cancer.

DOI： 10.1007/s00280-023-04607-7

Web of Science

PubMed

ASO Author Reflections: Association Between Preoperative Coagulation Status and Prognosis in Patients Undergoing Subtotal Esophagectomy for Esophageal Squamous Cell Carcinoma After Neoadjuvant Treatment Reviewed

Sugiyama, F; Kanda, M; Kodera, Y

ANNALS OF SURGICAL ONCOLOGY Vol. 31 ( 5 ) page： 3473 - 3474 2024.1

A multi-institutional prospective study to compare postoperative quality of life of patients who undergo proximal or total gastrectomy for early gastric cancer (CCOG1602). Reviewed

Kanda, M; Mochizuki, Y; Tanaka, C; Ito, S; Watanabe, T; Sueoka, S; Ishiyama, A; Yamada, T; Oshima, T; Hattori, M; Koike, S; Ishigure, K; Teramoto, H; Murotani, K; Kodera, Y

JOURNAL OF CLINICAL ONCOLOGY Vol. 42 ( 3_SUPPL ) page： 296 - 296 2024.1

Absence of Hypercoagulation Status after Neoadjuvant Treatment is Associated with Favorable Prognosis in Patients Undergoing Subtotal Esophagectomy for Esophageal Squamous Cell Carcinoma Reviewed

Sugiyama, F; Kanda, M; Shimizu, D; Umeda, S; Inokawa, Y; Hattori, N; Hayashi, M; Tanaka, C; Nakayama, G; Kodera, Y

ANNALS OF SURGICAL ONCOLOGY Vol. 31 ( 5 ) page： 3417 - 3425 2024.1

肥満外科治療の現状と課題当院における肥満外科治療の現状と課題 Reviewed

田中千恵, 中西香企, 清水大, 神田光郎, 小寺泰弘

日本消化管学会雑誌 Vol. 8 ( Suppl. ) page： 191 - 191 2024.1

Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer. Reviewed International journal

Osamu Maeda, Satoshi Furune, Mitsuro Kanda, Kazushi Miyata, Dai Shimizu, Shizuki Sugita, Kazuki Nishida, Masahiko Ando, Yasuhiro Kodera, Yuichi Ando

Cancer medicine Vol. 13 ( 2 ) page： e6974 2024.1

Language：English Publishing type：Research paper (scientific journal)

PURPOSE: A high risk of febrile neutropenia (FN) from neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for esophageal cancer has been reported. The optimal timing of prophylactic use of pegfilgrastim remains to be elucidated. To evaluate the effect of pegfilgrastim administered on day 3, we conducted a feasibility study. METHODS: Chemotherapy consisted of intravenous administration of docetaxel (70 mg/m2 per day) and cisplatin (70 mg/m2 per day) on day 1 and continuous infusion of 5-fluorouracil (750 mg/m2 per day) on days 1-5. Pegfilgrastim was given as a single subcutaneous injection at a dose of 3.6 mg on day 3 during each treatment course. This regimen was repeated every 3 weeks for up to a maximum of three courses. Prophylactic antibiotics were not needed but were allowed to be given at the discretion of the physician. The primary endpoint was the incidence of FN. RESULTS: Twenty-six patients were administered DCF in combination with pegfilgrastim on day 3. After the first course of DCF, 10 out of 26 patients (38.5%) experienced grade 4 neutropenia, and two patients (7.7%) experienced FN. Of the 14 patients who did not receive prophylactic antibiotics, four had grade 4 neutropenia, including two who developed FN. On the contrary, of the 12 patients who received prophylactic levofloxacin, six had grade 4 neutropenia, but no cases of FN were observed. CONCLUSION: Administration of pegfilgrastim on day 3 was not sufficient to prevent FN due to DCF treatment, and prophylactic administration of both pegfilgrastim and antibiotics could be a solution.

DOI： 10.1002/cam4.6974

Web of Science

PubMed

Increased STX3 transcript and protein levels were associated with poor prognosis in two independent cohorts of esophageal squamous cell carcinoma patients Reviewed

Shinozuka, T; Kanda, M; Sato, Y; Shimizu, D; Tanaka, C; Umeda, S; Inokawa, Y; Hattori, N; Hayashi, M; Nakayama, G; Kodera, Y

CANCER MEDICINE Vol. 12 ( 24 ) page： 22185 - 22195 2023.12

徐々に適応を拡大したロボット支援胃切除の短期成績 Reviewed

杉田静紀, 田中千恵, 宮田一志, 中西香企, 稲田亘佑, 田根雄一郎, 神田光郎, 清水大, 小寺泰弘, 江畑智希

日本内視鏡外科学会雑誌 Vol. 28 ( 7 ) page： 1969 - 1969 2023.12

噴門側胃切除における至適再建法当科における噴門側胃切除術後のダブルトラクト再建法の工夫と成績 Reviewed

田中千恵, 中西香企, 梅田晋一, 清水大, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 神田光郎, 中山吾郎, 藤原道隆, 小寺泰弘

日本内視鏡外科学会雑誌 Vol. 28 ( 7 ) page： 2033 - 2033 2023.12

トラブル例・緊急開腹移行例から考える安全な内視鏡外科手術-ロボット支援導入で変わるか- 当科の低侵襲手術におけるトラブルとその対処 Reviewed

田中千恵, 中西香企, 清水大, 梅田晋一, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 神田光郎, 中山吾郎, 藤原道隆, 小寺泰弘

日本内視鏡外科学会雑誌 Vol. 28 ( 7 ) page： 1608 - 1608 2023.12

クローン病再手術症例に対する低侵襲手術の治療成績 Reviewed

服部憲史, 中山吾郎, 梅田晋一, 岸田貴喜, 小倉淳司, 村田悠記, 中西香企, 清水大, 神田光郎, 田中千恵, 藤原道隆, 小寺泰弘

日本内視鏡外科学会雑誌 Vol. 28 ( 7 ) page： 2164 - 2164 2023.12

Proposal of the second cutoff of serum carcinoembryonic antigen levels to stratify patients into low, intermediate, and high risks at recurrences after curative resection of gastric cancer. Reviewed International journal

Bin Sato, Mitsuro Kanda, Seiji Ito, Yoshinari Mochizuki, Hitoshi Teramoto, Kiyoshi Ishigure, Toshifumi Murai, Takahiro Asada, Akiharu Ishiyama, Hidenobu Matsushita, Koki Nakanishi, Dai Shimizu, Chie Tanaka, Michitaka Fujiwara, Kenta Murotani, Yasuhiro Kodera

Digestive surgery Vol. 40 ( 6 ) page： 187 - 195 2023.12

Language：English Publishing type：Research paper (scientific journal)

INTRODUCTION: Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are widely used for various cancers, with the cut-off values of 5.0 ng/mL and 37.0 IU/mL, respectively. However, these cutoff values are not for specific diseases or purposes but are uniformly used for any disease and any purpose . It is also unclear as to whether patients are at equal risk of recurrence if they are below the cutoff values. This study aimed to investigate the optimal cutoff of serum tumor markers in the stratification of recurrence risk after curative resection of gastric cancer. METHODS: We constructed a nine-center integrated database of patients recieved gastrectomy between January 2010 and December 2014 with a 5-year follow-up period. We determined the cutoff value of preoperative serum tumor marker levels correlated with postoperative recurrences and evaluated its performance in risk stratification for recurrences in 948 patients with pStage II/III gastric cancer who underwent radical resection. RESULTS: The hazard ratio for postoperative recurrences increased at two points of preoperative CEA levels; 3.6 ng/mL and 5.0 ng/mL, which were set as cutoffs. These two cutoffs stratified relapse-free survival into three levels. CONCLUSIONS: By adding a second cutoff value for preoperative serum CEA, which was proposed specifically for the prediction of recurrences, patients can be stratified into low-, intermediate-, and high-risk recurrences after curative resection of gastric cancer.

DOI： 10.1159/000533143

Web of Science

PubMed

A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study Reviewed

Ooki, A; Aoyama, T; Oba, K; Nishikawa, K; Kawabata, R; Honda, M; Maeda, H; Kanda, M; Sugiyama, K; Makiyama, A; Segami, K; Takahashi, M; Shindo, Y; Namikawa, T; Oshima, T; Katayama, A; Shiosakai, K; Sakamoto, J

ANNALS OF ONCOLOGY Vol. 34 page： S1639 - S1640 2023.11

　 PREV - NEXT 　

<KANDA Mitsuro>

Papers - KANDA Mitsuro